NURPF (Neuren Pharmaceuticals) EBIT: $14.47 Mil (TTM As of Dec. 2025)


NURPF Neuren Pharmaceuticals Ltd NURPF
49 GF Score
Price $9.27
GF Value $4.40
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuren Pharmaceuticals EBIT?

Neuren Pharmaceuticals NURPF +6.67% 49 EBIT is $14.47 Mil as of Dec. 2025. GuruFocus rates NURPF with a GF Score™ of 49/100 and a GF Value™ of $4.40 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Neuren Pharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $7.39 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $14.47 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Neuren Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2025 was 51.76%. Neuren Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 103.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Neuren Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 1.47%.

Neuren Pharmaceuticals  (OTCPK:NURPF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Neuren Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=14.77 * ( 1 - 19.8% )/( (16.31 + 29.458)/ 2 )
=11.84554/22.884
=51.76 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=215.659 - 4.338 - ( 195.011 - max(0, 5.158 - 208.493+195.011))
=16.31

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=227.813 - 1.596 - ( 196.759 - max(0, 2.882 - 220.753+196.759))
=29.458

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Neuren Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=14.77/( ( (0.016 + max(8.324, 0)) + (0.03 + max(20.207, 0)) )/ 2 )
=14.77/( ( 8.34 + 20.237 )/ 2 )
=14.77/14.2885
=103.37 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.365 + 0 + 9.117) - (4.338 + 0 + 0.82)
=8.324

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.299 + 0 + 22.79) - (1.596 + 0 + 1.286)
=20.207

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Neuren Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=14.472/985.770
=1.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuren Pharmaceuticals EBIT Related Terms

Neuren Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Neuren Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuren Pharmaceuticals EBIT Chart

Neuren Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.18 -1.08 133.34 111.18 14.62

Neuren Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 101.12 2.69 108.61 7.09 7.39

NURPF vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Neuren Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuren Pharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Neuren Pharmaceuticals's EV-to-EBIT falls into.


NURPF
49GF Score
Neuren Pharmaceuticals Ltd NURPF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuren Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $14.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $14.47 Mil mean?
Neuren Pharmaceuticals (NURPF) has a EBIT of $14.47 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Neuren Pharmaceuticals.
Is Neuren Pharmaceuticals' EBIT too high?
Neuren Pharmaceuticals' current EBIT is $14.47 Mil. Overall, Neuren Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' EBIT compare to VRTX and REGN?
Neuren Pharmaceuticals' EBIT of $14.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Neuren Pharmaceuticals. Neuren Pharmaceuticals's current EBIT is $14.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (NURPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.40, compared to a current price of $9.27 — trading 110.7% above its estimated fair value. The current EBIT is $14.47 Mil. Neuren Pharmaceuticals' overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Neuren Pharmaceuticals (NURPF), the current EBIT is $14.47 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuren Pharmaceuticals (NURPF) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of $9.27 is trading 110.7% above its estimated GF Value™ of $4.40. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NURPF:

  • EBIT: $14.47 Mil
  • GF Value™: $4.40 vs. price of $9.27 (110.7% above fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the NURPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuren Pharmaceuticals Business Description

Other Exchanges NK9:GermanyNEU:Australia
Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
49GF Score

Get the complete analysis for NURPF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.27
Price
$4.40
GF Value